Date:

September 15, 2020

Time:

12:00 PM - 1:00 PM ET

Summary

On Tuesday, September 15, 12:00 p.m.-1:00 p.m. ET, the FDA will host a webinar to review these topics:

• Enforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency
• Umbrella Emergency Use Authorization (EUA) for Gowns and Other Apparel

This webinar will expand the scope of the webinar series from respirators and masks to gowns and other apparel.

During this webinar, the FDA will present information on both the enforcement policy and the EUA for gowns and other apparel, and representatives from the FDA, Centers for Disease Control and Prevention (CDC), and Occupational Safety and Health Administration (OSHA) will be available to answer your questions.  

We encourage all interested stakeholders to join. Registration is not necessary.

Add this to my Calendar
Outlook users: Click link, sel ect Open, then click Save & Close

SAVE THE DATE:

The FDA hosts a webinar every two weeks to share information and answer your questions about respirators and other personal protective equipment (PPE). Save the date for the next webinar:

• September 29, 2020, from 12:00 pm-1:00 pm ET

Background

In March 2020, the FDA issued the Enforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency guidance to provide a policy to help expand the availability of surgical apparel for health care professionals, including gowns (togas), hoods, and surgeon’s and patient examination gloves during this pandemic.

In May 2020, the FDA issued the Emergency Use Authorization (EUA) for gowns and other apparel in response to concerns relating to insufficient supply and availability of gowns and other apparel for use by health care personnel as personal protective equipment (PPE) for use in health care settings in accordance with Centers for Disease Control and Prevention (CDC) recommendations to protect both health care personnel and patients from the transfer of SARS-CoV-2, the virus that causes COVID-19, in low or minimal risk level situations to prevent the spread of COVID-19.

？